While there are no clinical analyses of cannabis for the treatment of diabetes mellitus in scientific literature, there still are a small number of preclinical studies that indicate the cannabinoids found in marijuana may provide symptomatic relief to people afflicted by diabetes mellitus. Medical marijuana is known to transform the development of the disease according to a 2006 study published in the journal auto-immunity.

The research reported that the 5 mg injections of the cbd oil merchant account non psychoactive cannabinoid CBD daily significantly reduced the incidence of diabetes in mice and researchers reported that while approximately 86 percent of untreated control mice in the study developed diabetes, by contrast only 30% of mice which were treated with CBD developed the disorder. Diabetes Mellitus identifies a set of auto immune diseases which are characterized by defects in the secretion of insulin in the pancreas. This results in hyperglycemia or a exceptionally significant concentration of sugar in the bloodcirculation.

While type 1 diabetes patients must count upon insulin medication for survival, sufferers of diabetes produce insufficient amounts of insulin and also their affliction might typically be controlled by diet. In fact, statistics indicate that after coronary problems and cancer, diabetes mellitus is the next important cause of death in the USA. It may also cause nerve damage, kidney failure, and blindness, hardening of the arteries, and eventually death.

Researchers at the Medical College of Virginia reported at the March 2006 issue of the American Journal of Pathology who CBD treated rats undergone significant protection against diabetic retinopathy when they were treated for extended periods of 1 to 4 weeks. Diabetic retinopathy, the main cause of blindness in adults is characterized by a breakdown of the blood-retinal barrier and bronchial oxygen deprivation. There are other preclinical trials which have demonstrated the favorable effects of cannabinoids in animal models of diabetes.

Medical marijuana is well known to ease neuropathic pain associated with diabetes mellitus and studies published in the journal Neuroscience Letters in 2004 reported that mice that were administered a receptor agonist for cannabis undergone a decline in diabetes related tactile allodynia or pain caused by a non-injurious skin stimulation when compared with the non treated controllers. These findings indicate that the cannabinoids at MMJ may have great therapeutic potential to take care of experimental neuropathic pain caused by diabetes mellitus.